Cassava Sciences, Inc. (SAVA)
NASDAQ: SAVA · Real-Time Price · USD
2.330
-0.080 (-3.32%)
Dec 19, 2024, 12:36 PM EST - Market open
Company Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences, Inc.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Richard Barry |
Contact Details
Address: 6801 N. Capital of Texas Highway, Suite 300 Austin, Texas 78731 United States | |
| Phone | 512 501 2444 |
| Website | cassavasciences.com |
Stock Details
| Ticker Symbol | SAVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001069530 |
| CUSIP Number | 14817C107 |
| ISIN Number | US14817C1071 |
| Employer ID | 91-1911336 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Jon Barry | Chief Executive Officer, President and Director |
| Eric J. Schoen | Chief Financial Officer |
| R. Christopher Cook J.D. | Senior Vice President, Company Secretary and General Counsel |
| Dr. James W. Kupiec M.D. | Chief Medical Officer |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology |
| Michael Zamloot | Senior Vice President of Technical Operations |
| Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs |
| Freda Nassif | Chief Commercial Officer |
| Jaren Landen | Chief Clinical Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2024 | 144 | Filing |
| Nov 29, 2024 | 144 | Filing |
| Nov 26, 2024 | SCHEDULE 13G/A | Filing |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 8, 2024 | 8-K | Current Report |
| Oct 1, 2024 | 8-K/A | [Amend] Current report |
| Sep 27, 2024 | 8-K | Current Report |